Teva Pharmaceutical Industries (TEVA) Change in Receivables (2025 - 2026)
Teva Pharmaceutical Industries (TEVA) posted Change in Receivables of -$78.0 million for Q1 2026, up 70.45% on a QoQ basis from -$264.0 million in Q1 2025, and up 70.45% year-over-year from -$45.8 million in Q1 2025.
Teva Pharmaceutical Industries (TEVA) Change in Receivables (2025 - 2026) Analysis & Trends
Teva Pharmaceutical Industries' Change in Receivables history runs 2 years deep, the most recent figure standing at -$78.0 million for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -38.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -78.00 Mn |
| Mar 31, 2026 | -78.00 Mn |
| Mar 31, 2025 | -264.00 Mn |
| Mar 31, 2025 | -264.00 Mn |